You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Dow
AstraZeneca
Mallinckrodt
Express Scripts

Last Updated: February 22, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for LGX818


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug LGX818?

LGX818 is an investigational drug.

There have been 20 clinical trials for LGX818. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.

The most common disease conditions in clinical trials are Melanoma, Colorectal Neoplasms, and Rectal Neoplasms. The leading clinical trial sponsors are Array BioPharma, National Cancer Institute (NCI), and Memorial Sloan Kettering Cancer Center.

There are twenty-one US patents protecting this investigational drug and three hundred and twenty-seven international patents.

Recent Clinical Trials for LGX818
TitleSponsorPhase
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node InvolvementNational Cancer Institute (NCI)Phase 2
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node InvolvementECOG-ACRIN Cancer Research GroupPhase 2
Encorafenib, Binimetinib, and Nivolumab in Treating Patients With Microsatellite Stable BRAFV600E Metastatic Colorectal CancerArray BioPharmaPhase 1/Phase 2

See all LGX818 clinical trials

Clinical Trial Summary for LGX818

Top disease conditions for LGX818
Top clinical trial sponsors for LGX818

See all LGX818 clinical trials

US Patents for LGX818

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LGX818   Start Trial Compounds and compositions as protein kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
LGX818   Start Trial Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-- pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate Array BioPharma Inc. (Boulder, CO)   Start Trial
LGX818   Start Trial Compounds and compositions as protein kinase inhibitors IRM LLC (Hamilton, BM) Novartis AG (Basel, CH)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Johnson and Johnson
McKesson
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.